Fosun Pharma receives acceptance for two drug applications

Shanghai Fosun Pharmaceutical (Group) Co. (HKEX:2196) announced that drug registration applications for Polymyxin B sulfate injection (Drug 1) by Guilin Pharmaceutical, and Labetalol Hydrochloride injection (Drug 2) by Shanghai Zhaohui Pharmaceutical, both subsidiaries, have been accepted by the National Medical Products Administration. Drug 1 is designed for gram-negative bacterial infections resistant to conventional treatments, while Drug 2 is for severe hypertension and controlling hypotension during anesthesia. As of December 2024, the Group's total investment in research and development for Drug 1 and Drug 2 totaled RMB4.88 million and RMB 2.09 million, respectively. According to IQVIA CHPA data from 2023, Polymyxin B sulfate injection in China had sales of approximately RMB1.703 billion, while Labetalol Hydrochloride Formulation was approximately RMB117 million. The company cautions that the approvals and subsequent market performance are subject to compliance inspections, market competition, and other factors.